@misc{Łosińska_Katarzyna_Biological_2023,
 author={Łosińska, Katarzyna},
 address={Kraków},
 howpublished={online},
 year={2023},
 school={Rada Dyscypliny Nauki medyczne},
 language={pol; eng},
 abstract={Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are the two most common chronic rheumatic diseases. Biological disease-modifying antirheumatic drugs (bDMARDs), both original and biosimilar, significantly increase the chances of achieving remission or low disease activity. However, the effects of therapy in everyday clinical practice differ from the results of clinical trials, which emphasizes the need to analyze real-world data. The aim of the study was to compare the efficacy of rituximab (RTX) and its biosimilar GP2013 in RA patients and to determine the relationship between the use of different bDMARDs and long-term changes in disease activity in PsA patients. Significant improvement in disease activity was shown in RA patients treated with RTX and stable efficacy of GP2013 comparable to the original drug. In PsA, an increase in the number of patients achieving remission was observed, which was associated with the introduction of new bDMARDs. Women with PsA achieved remission less often than men. The results varied significantly depending on the remission definition used, which indicates the need to revise the criteria for assessing both remission and low disease activity.},
 title={Biological disease-modifying anti-rheumatic drugs with a focus on rituximab in achieving remission and low disease activity in patients with rheumatoid arthritis and psoriatic arthritis},
 type={Praca doktorska},
 keywords={Rheumatoid arthritis, psoriatic arthritis, rituximab, GP2013, biosimilars},
}